rs369574719
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_000158.4(GBE1):c.785G>A(p.Arg262His) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000318 in 1,601,384 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000158.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBE1 | NM_000158.4 | c.785G>A | p.Arg262His | missense_variant, splice_region_variant | 7/16 | ENST00000429644.7 | NP_000149.4 | |
GBE1 | XR_007095662.1 | n.913G>A | splice_region_variant, non_coding_transcript_exon_variant | 7/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBE1 | ENST00000429644.7 | c.785G>A | p.Arg262His | missense_variant, splice_region_variant | 7/16 | 1 | NM_000158.4 | ENSP00000410833.2 | ||
GBE1 | ENST00000489715.1 | c.662G>A | p.Arg221His | missense_variant, splice_region_variant | 7/16 | 2 | ENSP00000419638.1 | |||
GBE1 | ENST00000498468.1 | n.335G>A | splice_region_variant, non_coding_transcript_exon_variant | 4/4 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 151998Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000298 AC: 7AN: 234522Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 126930
GnomAD4 exome AF: 0.0000297 AC: 43AN: 1449386Hom.: 0 Cov.: 28 AF XY: 0.0000236 AC XY: 17AN XY: 720640
GnomAD4 genome AF: 0.0000526 AC: 8AN: 151998Hom.: 0 Cov.: 32 AF XY: 0.0000674 AC XY: 5AN XY: 74206
ClinVar
Submissions by phenotype
Glycogen storage disease, type IV Pathogenic:2Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | May 03, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 20, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | May 18, 2021 | - - |
Uncertain significance, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 27, 2022 | The p.Arg262His variant in GBE1 has been reported in 1 individual, in a compound heterozygous state, with glycogen storage disease type IV (GSD IV) (PMID: 33332610) and has been identified in 0.02% (4/23286) of African/African American chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs369574719). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID#: 437422) and has been interpreted as likely pathogenic/pathogenic by Nilou-Genome lab and Center of Genomic medicine (Geneva, University Hospital of Geneva) and as uncertain significance by GeneDx and Counsyl. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Arg262His variant is uncertain. ACMG/AMP Criteria applied: PP3, PM3 (Richards 2015). - |
Adult polyglucosan body disease Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Feb 08, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center of Genomic medicine, Geneva, University Hospital of Geneva | Nov 15, 2016 | This heterozygous variant in the GBE1 gene (autosomal recessive transmission), inherited from the father, was present in a female patient who also harbours a second variant in the same codon of the same gene inherited by the mother (compound heterozygosity). - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 09, 2022 | Variant summary: GBE1 c.785G>A (p.Arg262His) results in a non-conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 3e-05 in 234522 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.785G>A in individuals affected with Glycogen Storage Disease, Type IV and no experimental evidence demonstrating its impact on protein function have been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 15, 2019 | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge - |
Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 10, 2022 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 262 of the GBE1 protein (p.Arg262His). This variant is present in population databases (rs369574719, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with GBE1-related conditions. ClinVar contains an entry for this variant (Variation ID: 437422). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at